Exchange: NASDAQ·Updated 08:16 AM EDT
ARVN logo

ARVN Arvinas Inc

$9.20
$0.00
(0.00%)
Pre-Market
Prev Close $9.20
Reported EarningsAug 4
Mkt Cap$601.55M
Vol88.00

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
43

Bearish Sentiment

How do you feel about ARVN?

Advertisement|Remove ads.